AIFA contributes to the protection of the right to health laid down by Article 32 of the Italian Constitution through the unity of the pharmaceutical system, through access to innovative medicines and orphan drugs for rare diseases, by ensuring the economic balance of the system in compliance with expenditure ceilings, through safe and appropriate use of medicines, investments in research and development in the pharmaceutical sector and by strengthening relations with agencies of other countries and with the EMA.
The strategic priorities identified in the 2019 Activity Plan are as follows:
- contributing to health promotion and protection through regulation of the marketing, use and supervision of medicinal products for human use;
- optimising the use of public resources allocated to reimbursement of medicines for human use to maximise the benefits of the community in terms of public health;
- promoting independent scientific information and fostering investments in research and development in the pharmaceutical sector.
Sense of belonging, responsibility, transparency, communication and confidentiality are the values and the strategic guidelines underpinning the daily work of the Agency.
Agenzia Italiana del Farmaco 
